Drug Profile
TF 6450
Alternative Names: TD-6450; TF-6450Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Theravance
- Developer Innoviva; Trek Therapeutics
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Sep 2021 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in New Zealand (PO)
- 28 Sep 2021 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(Monotherapy, Treatment-naive) in USA (PO, Capsule)